Single versus combinatorial therapies in status epilepticus: Novel data from preclinical models

Epilepsy and Behavior

Volumn 49, Issue , 2015, Pages 20-25

  Löscher, Wolfgang ^a,b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

Author keywords

Acetylcholine; Epilepsy; GABAA< inf> receptors; Ketamine; Neurodegeneration; NMDA receptors; Pharmacoresistance; Rational polytherapy; Scopolamine; Status epilepticus

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; AMPA RECEPTOR; ANESTHETIC AGENT; ATROPINE; BRIVARACETAM; CLONAZEPAM; DIAZEPAM; DOMOIC ACID; ETIRACETAM; FOSPHENYTOIN SODIUM; ISOFLURANE; KAINIC ACID; KETAMINE; LITHIUM; LORAZEPAM; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENOBARBITAL; PHENYTOIN; PILOCARPINE; POTASSIUM CHANNEL; SCOPOLAMINE; SOMAN; THIOPENTAL; VALPROIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT;

ADD ON THERAPY; BLOOD BRAIN BARRIER; CHOLINERGIC ACTIVITY; CHOLINERGIC STIMULATION; CYTOSOL; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ELECTROENCEPHALOGRAM; ENTORHINAL CORTEX; ENZYME INHIBITION; EPILEPTIC STATE; EPILEPTOGENESIS; GABAERGIC TRANSMISSION; HIPPOCAMPUS; HUMAN; MOTION SICKNESS; MULTICENTER STUDY (TOPIC); NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; POSTOPERATIVE NAUSEA AND VOMITING; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECURRENT DISEASE; RETROSPECTIVE STUDY; REVIEW; SEIZURE; TREATMENT DURATION; ANIMAL; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DISEASE MODEL; RAT; SEIZURES; STATUS EPILEPTICUS;

ANIMALS; ANTICONVULSANTS; DIAZEPAM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; KETAMINE; LITHIUM; PHENOBARBITAL; PILOCARPINE; RATS; SEIZURES; STATUS EPILEPTICUS;

EID: 84938982990     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2015.02.027     Document Type: Review

References (82)

1. Rossetti A.O., Lowenstein D.H. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol 2011, 10:922-930.
2. Treiman D.M. Treatment of convulsive status epilepticus. Int Rev Neurobiol 2007, 81:273-285.
3. Prasad M., Krishnan P.R., Sequeira R., Al Roomi K. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev 2014, 9:CD003723.
4. Neligan A., Shorvon S. Refractory versus non-refractory status epilepticus: frequency, differentiating clinical features, and outcome. Drug-resistant epilepsies. Progress in epileptic disorders 2008, vol. 7:29-46. John Libbey, Montrouge.
5. Löscher W. Molecular mechanisms of drug resistance in status epilepticus. Epilepsia 2009, 50(Suppl. 12):19-21.
6. Jones D.M., Esmaeil N., Maren S., Macdonald R.L. Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus. Epilepsy Res 2002, 50:301-312.
7. Chen J.W., Wasterlain C.G. Status epilepticus: pathophysiology and management in adults. Lancet Neurol 2006, 5:246-256.
8. Wasterlain C.G., Chen J.W. Mechanistic and pharmacologic aspects of status epilepticus and its treatment with new antiepileptic drugs. Epilepsia 2008, 49(Suppl. 9):63-73.
9. Wasterlain C.G., Liu H., Naylor D.E., Thompson K.W., Suchomelova L., Niquet J., et al. Molecular basis of self-sustaining seizures and pharmacoresistance during status epilepticus: the receptor trafficking hypothesis revisited. Epilepsia 2009, 50(Suppl. 12):16-18.
10. Curia G., Longo D., Biagini G., Niquet J., Jones R.S., Avoli M. The pilocarpine model of temporal lobe epilepsy. J Neurosci Methods 2008, 172:143-157.
11. Löscher W., Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev 2010, 62:668-700.
12. Pitkänen A., Nehlig A., Brooks-Kayal A.R., Dudek F.E., Friedman D., Galanopoulou A.S., et al. Issues related to development of antiepileptogenic therapies. Epilepsia 2013, 54(Suppl. 4):35-43.
13. Lemos T., Cavalheiro E.A. Suppression of pilocarpine-induced status epilepticus and the late development of epilepsy in rats. Exp Brain Res 1995, 102:423-428.
14. Glien M., Brandt C., Potschka H., Voigt H., Ebert U., Löscher W. Repeated low-dose treatment of rats with pilocarpine: low mortality but high proportion of rats developing epilepsy. Epilepsy Res 2001, 46:111-119.
15. Klitgaard H., Matagne A., Vanneste-Goemaere J., Margineanu D.G. Pilocarpine-induced epileptogenesis in the rat: impact of initial duration of status epilepticus on electrophysiological and neuropathological alterations. Epilepsy Res 2002, 51:93-107.
16. Rigoulot M.A., Koning E., Ferrandon A., Nehlig A. Neuroprotective properties of topiramate in the lithium-pilocarpine model of epilepsy. J Pharmacol Exp Ther 2004, 308:787-795.
17. Francois J., Koning E., Ferrandon A., Nehlig A. The combination of topiramate and diazepam is partially neuroprotective in the hippocampus but not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy. Epilepsy Res 2006, 72:147-163.
18. Jung K.H., Chu K., Lee S.T., Kim J., Sinn D.I., Kim J.M., et al. Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neurobiol Dis 2006, 23:237-246.
19. Chu K., Jung K.H., Lee S.T., Kim J.H., Kang K.M., Kim H.K., et al. Erythropoietin reduces epileptogenic processes following status epilepticus. Epilepsia 2008, 49:1723-1732.
20. Doeser A., Dickhof G., Reitze M., Uebachs M., Schaub C., Pires N.M., et al. Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug. Brain 2014, 138:371-387.
21. Reddy D.S., Kuruba R. Experimental models of status epilepticus and neuronal injury for evaluation of therapeutic interventions. Int J Mol Sci 2013, 14:18284-18318.
22. Rajasekaran K., Zanelli S.A., Goodkin H.P. Lessons from the laboratory: the pathophysiology, and consequences of status epilepticus. Semin Pediatr Neurol 2010, 17:136-143.
23. Ellerkmann R.K., Remy S., Chen J., Sochivko D., Elger C.E., Urban B.W., et al. Molecular and functional changes in voltage-dependent Na(+) channels following pilocarpine-induced status epilepticus in rat dentate granule cells. Neuroscience 2003, 119:323-333.
24. Remy S., Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 2006, 129:18-35.
25. Lugo J.N., Barnwell L.F., Ren Y., Lee W.L., Johnston L.D., Kim R., et al. Altered phosphorylation and localization of the A-type channel, Kv4.2 in status epilepticus. J Neurochem 2008, 106:1929-1940.
26. Bankstahl J.P., Löscher W. Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus. Epilepsy Res 2008, 82:70-85.
27. Kuteykin-Teplyakov K., Brandt C., Hoffmann K., Löscher W. Complex time-dependent alterations in the brain expression of different drug efflux transporter genes after status epilepticus. Epilepsia 2009, 50:887-897.
28. Henshall D.C., Diaz-Hernandez M., Miras-Portugal M.T., Löscher W., Engel T. P2X receptors as targets for the treatment of status epilepticus. Front Cell Neurosci 2013, 7:237.
29. Löscher W., Klitgaard H., Twyman R.E., Schmidt D. New avenues for antiepileptic drug discovery and development. Nat Rev Drug Discov 2013, 12:757-776.
30. Brandt C., Töllner K., Klee R., Bröer S., Löscher W. Effective termination of status epilepticus by rational polypharmacy in the lithium-pilocarpine model in rats: window of opportunity to prevent epilepsy and prediction of epilepsy by biomarkers. Neurobiol Dis 2015, 75:78-90.
31. Löscher W. The pharmacokinetics of antiepileptic drugs in rats: consequences for maintaining effective drug levels during prolonged drug administration in rat models of epilepsy. Epilepsia 2007, 48:1245-1258.
32. Bourin M., Hascoet M., Mansouri B., Colombel M.C., Bradwejn J. Comparison of behavioral effects after single and repeated administrations of four benzodiazepines in three mice behavioral models. J Psychiatry Neurosci 1992, 17:72-77.
33. DrugBank Version 4.1 2015, (http://www.drugbank.ca/).
34. Barnhill J.G., Greenblatt D.J., Miller L.G., Gaver A., Harmatz J.S., Shader R.I. Kinetic and dynamic components of increased benzodiazepine sensitivity in aging animals. J Pharmacol Exp Ther 1990, 253:1153-1161.
35. Mandema J.W., Tukker E., Danhof M. Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. Br J Pharmacol 1991, 102:663-668.
36. Granvil C.P., Yu A.M., Elizondo G., Akiyama T.E., Cheung C., Feigenbaum L., et al. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug Metab Dispos 2003, 31:548-558.
37. Markowitz G.J., Kadam S.D., Boothe D.M., Irving N.D., Comi A.M. The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. Neuroreport 2010, 21:452-456.
38. Mullen P.W. Pharmacokinetics of phenytoin and liver cytochrome P-450 levels in mice after single doses of Corynebacterium parvum [proceedings]. Br J Pharmacol 1979, 67:470P-472P.
39. Koo T.S., Kim S.J., Ha D.J., Baek M., Moon H. Pharmacokinetics, brain distribution, and plasma protein binding of the antiepileptic drug lacosamide in rats. Arch Pharm Res 2011, 34:2059-2064.
40. Kukongviriyapan V., Simajareuk S., Kukongviriyapan U., Cha-on U., Airarat W. Alteration of drug kinetics in rats following exposure to trichloroethylene. Pharmacology 2001, 63:90-94.
41. Graham J.A., Menzel D.B., Mole M.L., Miller F.J., Gardner D.E. Influence of ozone on pentobarbital pharmacokinetics in mice. Toxicol Lett 1985, 24:163-170.
42. Yu H.Y., Sawada Y., Sugiyama Y., Iga T., Hanano M. Effect of sulfadimethoxine on thiopental distribution and elimination in rats. J Pharm Sci 1981, 70:323-326.
43. Adam H.K., Glen J.B., Hoyle P.A. Pharmacokinetics in laboratory animals of ICI 35 868, a new i.v. anaesthetic agent. Br J Anaesth 1980, 52:743-746.
44. Guan L., Wu X.M., Jiang J.Y. Elimination half-life of propofol in effect-site of mice. Beijing Da Xue Xue Bao 2005, 37:187-189.
45. Veilleux-Lemieux D., Castel A., Carrier D., Beaudry F., Vachon P. Pharmacokinetics of ketamine and xylazine in young and old Sprague-Dawley rats. J Am Assoc Lab Anim Sci 2013, 52:567-570.
46. Maxwell C.R., Ehrlichman R.S., Liang Y., Trief D., Kanes S.J., Karp J., et al. Ketamine produces lasting disruptions in encoding of sensory stimuli. J Pharmacol Exp Ther 2006, 316:315-324.
47. Atlas S.A., Zweier J.L., Nebert D.W. Genetic differences in phenytoin pharmacokinetics. In vivo clearance and in vitro metabolism among inbred strains of mice. Dev Pharmacol Ther 1980, 1:281-304.
48. Olsen R.W. GABA-drug interactions. Prog Drug Res 1987, 31:223-241.
49. Buterbaugh G.G., Michelson H.B., Keyser D.O. Status epilepticus facilitated by pilocarpine in amygdala-kindled rats. Exp Neurol 1986, 94:91-102.
50. Jope R.S., Morrisett R.A., Snead O.C. Characterization of lithium potentiation of pilocarpine-induced status epilepticus in rats. Exp Neurol 1986, 91:471-480.
51. Clifford D.B., Olney J.W., Maniotis A., Collins R.C., Zorumski C.F. The functional anatomy and pathology of lithium-pilocarpine and high-dose pilocarpine seizures. Neuroscience 1987, 23:953-968.
52. Morrisett R.A., Jope R.S., Snead O.C. Effects of drugs on the initiation and maintenance of status epilepticus induced by administration of pilocarpine to lithium-pretreated rats. Exp Neurol 1987, 97:193-200.
53. George B., Kulkarni S.K. Protective effects of GABAergic drugs and other anticonvulsants in lithium-pilocarpine-induced status epilepticus. Methods Find Exp Clin Pharmacol 1996, 18:335-340.
54. Omori Y., Endo T., Hara Y., Nishiyama M., Midgley I., Smart C.I., et al. Absorption, distribution and excretion of 14C-pilocarpine following oral administration to rats. Arzneimittelforschung 2004, 54:171-178.
55. Bradford H.F., Peterson D.W. Current views of the pathobiochemistry of epilepsy. Mol Aspects Med 1987, 9:119-172.
56. Wasterlain C.G., Fujikawa D.G., Penix L., Sankar R. Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia 1993, 34(Suppl. 1):S37-S53.
57. Friedman A., Behrens C.J., Heinemann U. Cholinergic dysfunction in temporal lobe epilepsy. Epilepsia 2007, 48(Suppl. 5):126-130.
58. Steinlein O.K., Bertrand D. Nicotinic receptor channelopathies and epilepsy. Pflugers Arch 2010, 460:495-503.
59. McGeer E.G., McGeer P.L. Substantia nigra cell death from kainic acid or folic acid injections into the pontine tegmentum. Brain Res 1984, 298:339-342.
60. Sobotka T.J., Brown R., Quander D.Y., Jackson R., Smith M., Long S.A., et al. Domoic acid: neurobehavioral and neurohistological effects of low-dose exposure in adult rats. Neurotoxicol Teratol 1996, 18:659-670.
61. Pereira H.A., Benassi S.K., Mello L.E. Plastic changes and disease-modifying effects of scopolamine in the pilocarpine model of epilepsy in rats. Epilepsia 2005, 46(Suppl. 5):118-124.
62. Arnold P.S., Racine R.J., Wise R.A. Effects of atropine, reserpine, 6-hydroxydopamine, and handling on seizure development in the rat. Exp Neurol 1973, 40:457-470.
63. Cain D.P., McKitrick D.J., Desborough K.A. Effects of treatment with scopolamine and naloxone, singly and in combination, on amygdala kindling. Exp Neurol 1987, 96:97-103.
64. Westerberg V., Corcoran M.E. Antagonism of central but not peripheral cholinergic receptors retards amygdala kindling in rats. Exp Neurol 1987, 95:194-206.
65. Adams B., Vaccarella L., Fahnestock M., Racine R.J. The cholinergic system modulates kindling and kindling-induced mossy fiber sprouting. Synapse 2002, 44:132-138.
66. Mazarati A.M., Wasterlain C.G. N-methyl-d-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci Lett 1999, 265:187-190.
67. Dorandeu F., Dhote F., Barbier L., Baccus B., Testylier G. Treatment of status epilepticus with ketamine, are we there yet?. CNS Neurosci Ther 2013, 19:411-427.
68. Wasterlain C.G., Baldwin R., Naylor D.E., Thompson K.W., Suchomelova L., Niquet J. Rational polytherapy in the treatment of acute seizures and status epilepticus. Epilepsia 2011, 52(Suppl. 8):70-71.
69. Dorandeu F., Carpentier P., Baubichon D., Four E., Bernabe D., Burckhart M.F., et al. Efficacy of the ketamine-atropine combination in the delayed treatment of soman-induced status epilepticus. Brain Res 2005, 1051:164-175.
70. Martin B.S., Kapur J. A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation. Epilepsia 2008, 49:248-255.
71. Mazarati A.M., Baldwin R., Klitgaard H., Matagne A., Wasterlain C.G. Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res 2004, 58:167-174.
72. Brophy G.M., Bell R., Claassen J., Alldredge B., Bleck T.P., Glauser T., et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012, 17:3-23.
73. Rantsch K., Walter U., Wittstock M., Benecke R., Rosche J. Treatment and course of different subtypes of status epilepticus. Epilepsy Res 2013, 107:156-162.
74. Treiman D.M., Meyers P.D., Walton N.Y., Collins J.F., Colling C., Rowan A.J., et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998, 339:792-798.
75. Sreenath T.G., Gupta P., Sharma K.K., Krishnamurthy S. Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: a randomized controlled trial. Eur J Paediatr Neurol 2010, 14:162-168.
76. Pitkänen A., Wasterlain C.C. Commentary: translation of laboratory findings to clinic in the treatment of status epilepticus - a mission impossible?. Epilepsia 2009, 50:1834-1835.
77. Zeiler F.A. Early use of the NMDA receptor antagonist ketamine in refractory and superrefractory status epilepticus. Crit Care Res Pract 2015, 2015:831260.
78. Hocker S., Tatum W.O., Laroche S., Freeman W.D. Refractory and super-refractory status epilepticus - an update. Curr Neurol Neurosci Rep 2014, 14:452.
79. Shorvon S., Ferlisi M. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain 2012, 135:2314-2328.
80. Hönack D., Löscher W. Intravenous valproate: onset and duration of anticonvulsant activity against a series of electroconvulsions in comparison with diazepam and phenytoin. Epilepsy Res 1992, 13:215-221.
81. Perucca E. What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate. Epilepsia 2009, 50(Suppl. 12):49-50.
82. Hillert M.H., Imran I., Zimmermann M., Lau H., Weinfurter S., Klein J. Dynamics of hippocampal acetylcholine release during lithium-pilocarpine-induced status epilepticus in rats. J Neurochem 2014, 131:42-52.